world
Small Study Shows Modified Immune Cells Suppress HIV in Two Patients
Researchers reported that a single dose of genetically engineered CAR-T cells strongly suppressed HIV in two people for nearly one and two years without daily medication. The early-stage experiment modified immune cells to better target HIV-infected cells while protecting them from infection. Larger studies are needed to determine if the approach could lead to long-term remission.
May 12, 11:08 AM·2m read1 source
The IndependentAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Scientists are testing a modification of CAR-T cell therapy, a treatment widely used for certain cancers, to see if it can help fight HIV. On Tuesday, researchers said a single dose of the revved-up immune cells strongly suppressed HIV in two people — one for nearly a year and the other for nearly two years — after they stopped their usual antiviral medicines.
The findings were presented at a meeting of the American Society of Gene and Cell Therapy in Boston. The study leader said the sustained responses were provocative given the challenge of finding an HIV cure. Larger and longer studies are required to establish whether the therapy can provide lasting benefit.
40 million people live with HIV worldwide.
Current medicines can keep the virus at undetectable levels and turn AIDS into a manageable chronic condition, but only if patients can access the drugs and adhere to lifelong treatment. The virus hides in reservoirs in the body and typically rebounds quickly if treatment stops.
Researchers have sought a cure for decades, examining rare genetic mutations that confer natural resistance and cases in which stem cell transplants from donors with such mutations have led to remission in patients who also had cancer. Those transplants carry high risks and are not feasible for most people with HIV.
How the CAR-T Approach Was Adapted CAR-T therapy involves extracting a patient's T cells, genetically modifying them into living drugs, and infusing them back into the body. For HIV, scientists created CAR-T cells with two features: they are programmed to locate and kill HIV-infected cells, and they are engineered to resist infection by the virus itself.
